Premium
Front Cover: Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model
Author(s) -
Germany Caroline E.,
Reker Ashlie N.,
Hinton David J.,
Oliveros Alfredo,
Shen Xinggui,
AndresBeck Lindsey G.,
Wininger Katheryn M.,
Trutschl Marjan,
Cvek Urska,
Choi DooSup,
Nam Hyung W.
Publication year - 2018
Publication title -
proteomics
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201870051
Subject(s) - acamprosate , pharmacology , animal model , drug , medicine , naltrexone , receptor , opioid
DOI: 10.1002/pmic.201700417 Pharmacoproteomics is an approach for determining molecular signaling changes correlated with drug efficacy. In article number 1700417 , Germany et.al. investigated proteome changes in the brain associated with acamprosate treatment outcome using alcoholism animal model, type 1 equilibrative nucleoside transporter (ENT1) null mice. Pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub‐populations of alcohol‐dependent patients.